83067-94-1

Upstream product

• 462-08-8 pyridin-3-ylamine 
• 87-13-8 diethyl 2-ethoxymethylenemalonate 
• 14029-71-1 2-(pyridin-3-yl)aminomethylene-malonic acid diethyl ester 

Downstream Products

• 83067-95-2 4-chloro-1,5-naphthyridine-3-carboxylic acid ethyl ester 
• 83068-00-2 3-Carboxy-4-amino-1,5-naphthyridine 
• 83068-01-3 3-Carboxy-4-anilino-1,5-naphthyridine 
• 83068-06-8 1-Phenyl-3-hydroxypyrazolo<4,3-c>-1,5-naphthyridine 
• 83068-07-9 1H-2-Phenyl-3-oxo-2,3-dihydropyrazolo<4,3-c>-1,5-naphthyridine 
• 83067-98-5 3-Ethoxycarbonyl-4-phenylamino-1,5-napthyridine 
• 83068-03-5 3-Ethoxycarbonyl-4-benzylthio-1,5-naphthyridine 
• 1279716-19-6 ethyl 4-oxo-1-{[4-(1H-pyrazol-1-yl)phenyl]methyl}-1,4-dihydro-1,5-naphthyridine-3-carboxylate 
• 1279716-20-9 ethyl 1-{[4-(1H-pyrazol-1-yl)phenyl]methyl}-4-thioxo-1,4-dihydro-1,5-naphthyridine-3-carboxylate 
• 1279716-21-0 5-{[4-(1H-pyrazol-1-yl)phenyl]methyl}-2,5-dihydro-3H-pyrazolo[4,3-c]-1,5-naphthyridin-3-one 
• 1279716-02-7 2-(2-fluorophenyl)-5-{[4-(1H-pyrazoI-1-yI)phenyl]methyl}-2,5-dihydro-3H-pyrazolo[4,3-c]-1,5-naphthyridin-3-one 
• 1617540-19-8 ethyl 1-((4'-chlorobiphenyl-2-yl)methyl)-4-oxo-1,4-dihydro-1,5-naphthyridine-3-carboxylate 
• 1617540-16-5 ethyl 1-(2-(4-chlorophenylthio)benzyl)-4-oxo-1,4-dihydro-1,5-naphthyridine-3-carboxylate 
• 1617540-17-6 1-((4'-chlorobiphenyl-2-yl)methyl)-4-oxo-1,4-dihydro-1,5-naphthyridine-3-carboxylic acid 

Relevant academic research and scientific papers

NAPHTHYRIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE

The present invention relates to a compound having the general formula (V), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, codrug, cocrystal, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which are useful in treating, ameloriating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.

HETEROCYCLIC-FUSED PYRAZOLO[4,3-c]PYRIDIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS

The present invention is directed to heterocyclic fused pyrazole [4,3-c] pyridine-3-one compounds of formula (I): which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, s

Synthesis and structure-activity relationship studies of dihydronaphthyridinediones as a novel structural class of potent and selective PDE7 inhibitors

The synthesis and SAR studies of a series of structurally novel inhibitors of PDE7 are discussed. The best compounds from the series display low nanomolar inhibitory activity and are selective versus other PDE isoenzymes.

Pharmacomodulations around the 4-oxo-1,4-dihydroquinoline-3-carboxamides, a class of potent CB2-selective cannabinoid receptor ligands: Consequences in receptor affinity and functionality

CB2 receptor selective ligands are becoming increasingly attractive drugs due to the potential role of this receptor in several physiopathological processes. Thus, the development of our previously described series of 4-oxo-1,4-dihydroquinoline-3-carboxamides was pursued with the aim to further characterize the structure-affinity and structure-functionality relationships of these derivatives. The influence of the side chain was investigated by synthesizing compounds bearing various carboxamido and keto substituents. On the other hand, the role of the quinoline central scaffold was studied by synthesizing several 6-, 7-, or 8-chloro-4-oxo-1,4-dihydroquinolines, as well as 4-oxo-1,4-dihydronaphthyridine and 4-oxo-1,4-dihydrocinnoline derivatives. The effect of these modifications on the affinity and functionality at the CB2 receptor was studied and allowed for the characterization of new selective CB2 receptor ligands.